Feature | December 21, 2010

Report Presents New Recommendations on Sudden Cardiac Death Prediction and Prevention

December 21, 2010 - The outcome of a recent expert consensus workshop offers six specific research recommendations in high-priority areas for sudden cardiac death (SCD) prediction and prevention. In the United States, SCD claims more than 250,000 lives annually and is the cause of half of all heart disease deaths. The report, “Sudden Cardiac Death (SCD) Prediction and Prevention: Report from a National Heart, Lung and Blood Institute (NHLBI) and Heart Rhythm Society Workshop,” was published in the November 30th issue of Circulation, an official journal of the American Heart Association.

The purpose of the workshop was to discover emerging approaches for improved prediction and prevention of SCD. The expert panel, which consisted of 24 arrhythmia investigators, was asked to consider the three broad areas of basic, clinical and population sciences.

“With the support of HRS and NHLBI, the workshop provided a unique venue to tackle complex biomedical issues,” said Glenn Fishman, M.D., FHRS, at New York University. “It afforded experts the opportunity to challenge old concepts and debate new ideas, with the hope that our individual and collective creativity would provide a useful roadmap for future exploration.”

The report outlines the outcomes of the expert consensus workshop – identifying knowledge gaps and a series of six specific recommendations for future research approaches in order to improve the prediction and prevention of SCD. Recommendations (not prioritized):

• Establish multi-scale integrative models, utilizing molecular, cellular, organ-level, animal and computational approaches, and apply these models to determine arrhythmia mechanisms.
• Establish high throughput experimental strategies to rapidly determine the functional relevance of newly discovered genes associated with arrhythmias in humans.
• Develop novel risk stratification strategies to improve outcomes in select populations, including those with ICD indications.
• Facilitate study of well-phenotyped SCD and control populations, including understudied subgroups.
• Develop and validate a SCD risk score utilizing phenotypic, biologic and non-invasive markers.
• Establish strategies for SCD prevention that can be employed in the general population, targeting intermediate risk phenotypes.

“This report is critical to helping us identify limitations of current understanding and point the way to the most fruitful research avenues for the future,” said Douglas Packer, president of the Heart Rhythm Society, M.D., FHRS. “The Society is pleased to collaborate with the NHLBI and we will continue our efforts toward innovation in electrophysiology and the prevention of sudden death for years to come.”

For more information: www.hrsonline.org

Related Content

News | Heart Failure| August 28, 2015
August 28, 2015 — BioControl Medical said it has completed enrollment in its INOVATE-HF (INcrease Of VAgal TonE in He
BioSig Technologies, research agreement, UCLA, Pure EP System, EP lab, ventricular tachycardia model, VT
Technology | EP Lab| August 20, 2015
BioSig Technologies announced it has signed a sponsored research agreement with the regents of the University of...
Sunshine Heart, COUNTER HF pivotal study, resumes enrollment, C-Pulse, FDA
News | Heart Failure| August 18, 2015
Sunshine Heart Inc. announced an update in late July on its COUNTER HF U.S. pivotal study for the C-Pulse Heart Assist...
Biotronik, BioCONTINUE study, CRT-D, defibrillator, cardiac resynchronization therapy device, heart failure, first replacement
News | Cardiac Resynchronization Therapy Devices (CRT)| August 17, 2015
Biotronik announced that the first patient has been enrolled in the BioCONTINUE clinical trial (BIOtronik study to...
CMS, additional participants, Bundled Payments for Care Improvement initiative, Medicare, eipsodes of care
News | Business| August 17, 2015
The Centers for Medicare & Medicaid Service (CMS) announced that over 2,100 healthcare facilities have agreed to...
HeartWare, ENDURANCE2 trial, destination therapy, HVAS, HeartWare Ventricular Assist System
News | Ventricular Assist Devices (VAD)| August 11, 2015
HeartWare International Inc. announced that enrollment in the ENDURANCE2 destination therapy clinical trial has been...
Biotronik, BIOGUARD-MI Study, BioMonitor, cardiac arrhythmias, early detection, remote monitoring
News | Implantable Cardiac Monitor (ICM)| August 11, 2015
Biotronik announced the first enrollments in the BIO|GUARD-MI1 study. The study will investigate whether the early...
Boston Scientific, Preventice Solutions, equity investment, sales cooperation agreement, cardiac monitoring

BodyGuardian product family. Image courtesy of Preventice Solutions.

News | Remote Monitoring| August 11, 2015
Boston Scientific has become a significant shareholder and will become the exclusive worldwide sales and marketing...
Passive Elastography, TTP, U.K., ablation, atrial fibrillation
News | Cardiovascular Ultrasound| August 10, 2015
The Technology Partnership (TTP), a U.K.-based research and product development company, has made major advances in the...
Overlay Init